PARP1 and cancer: PARP inhibitors have shown promise in cancer therapy via a mechanism dependent on synthetic lethality; the inhibition of PARP results in the accumulation of a significant amount of double-strand breaks (DSB) by interfering with replication fork progression at the site of DNA damage [6].